SCIENCE@home

Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs.

Xiancheng Chen,Rui Wang,Xia Zhao,Yu‐quan Wei,Min Hu,Yang-sheng Wang,Xiao-wei Zhang,Ru Zhang,Lin Zhang,Bing Yao,Lian Wang,Yong-qian Jia,Tingting Zeng,Jin-liang Yang,L. Tian,B. Kan,Xiao-juan Lin,S. Lei,H. Deng,Y. Wen,Yong‐qiu Mao,Jiong Li

Published 2006 in Carcinogenesis

ABSTRACT

Mesenchymal stem cells (MSCs) were adenovirally engineered to secrete interleukin-12 (AdIL-12-MSCs) and evaluated for their anticarcinogenesis efficacy against three kinds of unestablished tumor models including B16 melanoma, LLC Lewis lung cancer and HCC hepatoma. Injection of AdIL-12-MSCs into protected mice before tumor inoculation prevented all of 12 mice in B16 preventive groups, 10 out of 12 in LLC lung cancer model and 11 out of 12 mice in HCC hepatoma model from developing tumors, whereas the control groups pre-receiving PBS were validated for 100% carcinogenesis; the tumor formation rates in free-AdIL-12 and vacant MSC groups were unveiled between approximately 83 and 100% even with plentiful angiogenesis and newborn lymphatic vessels, as well as distant metastases. As a novel approach, AdIL-12-MSC has revealed expected preventive effects on carcinogenesis (P<0.01) with low-toxic, broad-spectrum and long-range superiorities. In conclusion, our data indicate that AdIL-12-MSC possess the potential for tropism to preclinical tumor lesions and deprives surviving or hibernating tumor cells, which have escaped from conventional treatments, of revival and recurrence.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-58 of 58 references · Page 1 of 1

CITED BY

Showing 1-87 of 87 citing papers · Page 1 of 1